2024
Comparison of chemotherapy to chemo-immunotherapy as first-line treatment in patients with advanced large cell neuroendocrine carcinomas (LCNECs) of mixed histology: A multi-institutional international retrospective study.
Matteson K, Nassar A, Ellis-Caleo T, Mingo E, Aggarwal V, Sridhar A, Alam S, Crowley F, Aboubakar Nana F, Ahmed M, Grohe C, Zurera Berjaga M, Pinato D, Watson A, Chiang A, Naqash A. Comparison of chemotherapy to chemo-immunotherapy as first-line treatment in patients with advanced large cell neuroendocrine carcinomas (LCNECs) of mixed histology: A multi-institutional international retrospective study. Journal Of Clinical Oncology 2024, 42: 8602-8602. DOI: 10.1200/jco.2024.42.16_suppl.8602.Peer-Reviewed Original ResearchProgression-free survivalTreatment-related adverse eventsFirst-line treatmentMedian progression-free survivalOverall survivalChemo-immunotherapyMedian OSLung cancerAll-grade treatment-related adverse eventsRare subtype of lung cancerMulti-institutional retrospective analysisSmall cell lung cancerCell neuroendocrine carcinomaInternational retrospective studyCell lung cancerSubtype of lung cancerLog-rank testFeatures of adenocarcinomaOptimal treatment approachClinical trial dataChemo-regimensNeuroendocrine carcinomaChemo groupSystemic therapyRare subtypeAbstract 971: Validation of a tumor-naïve circulating tumor DNA (ctDNA) response monitoring panel in advanced non-small cell lung cancer (aNSCLC)
Chiang A, Madison R, Huang Y, Fine A, Jin D, Oxnard G, Hughes J, Assaf Z, Cao Y, Antic V, Gjoerup O, Young A, Fabrizio D, Lakhanpal S, Zuniga R, Schulze K, Pasquina L. Abstract 971: Validation of a tumor-naïve circulating tumor DNA (ctDNA) response monitoring panel in advanced non-small cell lung cancer (aNSCLC). Cancer Research 2024, 84: 971-971. DOI: 10.1158/1538-7445.am2024-971.Peer-Reviewed Original ResearchAdvanced non-small cell lung cancerPeripheral blood mononuclear cellsNon-small cell lung cancerRisk of progressionCell lung cancerClonal hematopoiesisTumor fractionGenomic alterationsTumor signalAmerican Association for Cancer Research annual meetingsLung cancerHazard ratioPatient's risk of progressionFrequency of genomic alterationsAssociated with favorable outcomesMolecular responseWeeks of TxProgression free survivalUnivariate Cox proportional hazards regressionCox proportional hazards regressionBlood mononuclear cellsConfidence intervalsVariant allele frequencyCombination of aneuploidyProportional hazards regression214TiP Tarlatamab after chemoradiotherapy in limited-stage small cell lung cancer (LS-SCLC): DeLLphi-306 (NCT06117774)
Hummel H, Paz-Ares L, Blackhall F, Chiang A, Dowlati A, Goldman J, Izumi H, Mok T, Sands J, Martinez P, Anderson E, Bharania P, Yu B, Yu Y, Pulla M. 214TiP Tarlatamab after chemoradiotherapy in limited-stage small cell lung cancer (LS-SCLC): DeLLphi-306 (NCT06117774). ESMO Open 2024, 9: 102787. DOI: 10.1016/j.esmoop.2024.102787.Peer-Reviewed Original Research
2023
Differential Effect of Consolidative Thoracic Radiation Therapy in Extensive-Stage Small Cell Lung Cancer Based on Sex
Jairam V, Soulos P, Madhav K, Gross C, Slotman B, Chiang A, Park H. Differential Effect of Consolidative Thoracic Radiation Therapy in Extensive-Stage Small Cell Lung Cancer Based on Sex. Advances In Radiation Oncology 2023, 9: 101413. PMID: 38778819, PMCID: PMC11110031, DOI: 10.1016/j.adro.2023.101413.Peer-Reviewed Original ResearchExtensive-stage small-cell lung cancerConsolidative thoracic radiotherapyProgression-free survivalSmall cell lung cancerCell lung cancerCREST trialThoracic radiotherapyLung cancerElectronic health record-derived databaseFirst-line systemic therapyStandard first-line treatmentCox proportional hazards regressionFirst-line treatmentNational practice patternsProportional hazards regressionSuperior OSInitial chemotherapyBaseline characteristicsSystemic therapyMale patientsFemale patientsPatient sexHazards regressionSurvival outcomesPractice patternsMutation-specific costs of advanced non-small cell lung cancer treatment.
Tan J, Yang S, Dinan M, Chiang A, Gross C, Wang S. Mutation-specific costs of advanced non-small cell lung cancer treatment. JCO Oncology Practice 2023, 19: 14-14. DOI: 10.1200/op.2023.19.11_suppl.14.Peer-Reviewed Original ResearchAdvanced non-small cell lung cancerNon-small cell lung cancerMean medication costsActionable gene alterationsMedication costsFirst-year costsReference groupAdvanced non-small cell lung cancer (NSCLC) treatmentNon-small cell lung cancer (NSCLC) treatmentCell lung cancer treatmentGene alterationsBiomarker resultsFlatiron Health databasePD-L1 resultsTherapy prolongs survivalRetrospective cohort studyCell lung cancerBiomarker test resultsLung cancer treatmentCost-effectiveness analysisCohort studyNovel immunotherapiesOverall cohortProlong survivalTreatment optionsUsing real world practice patterns to identify clinical equipoise in cancer treatment: Advanced non-small cell lung cancer as an exemplar.
Li Y, Yang S, Chiang A, Gross C, Wang S. Using real world practice patterns to identify clinical equipoise in cancer treatment: Advanced non-small cell lung cancer as an exemplar. JCO Oncology Practice 2023, 19: 539-539. DOI: 10.1200/op.2023.19.11_suppl.539.Peer-Reviewed Original ResearchNon-small cell lung cancerAdvanced non-small cell lung cancerPD-L1 1First-line therapyCell lung cancerTreatment patternsECOG 2PD-L1Clinical equipoiseLung cancerHHI scoresEastern Cooperative Oncology Group performance scoreFirst-line treatment regimensReal-world practice patternsALK/EGFRActionable gene alterationsStandard of careConfidence intervalsGroup performance scoreComparative effectiveness researchECOG statusOverall cohortPerformance statusECOG scoreTreatment regimens
2022
KeyVibe-008: Randomized, phase 3 study of first-line vibostolimab plus pembrolizumab plus etoposide/platinum versus atezolizumab plus EP in extensive-stage small cell lung cancer.
Sands J, Reck M, Navarro A, Chiang A, Lu S, Peled N, Paz-Ares L, Kerr S, Takahashi T, Smolin A, Chen X, Zhao B, El-Osta H, Califano R. KeyVibe-008: Randomized, phase 3 study of first-line vibostolimab plus pembrolizumab plus etoposide/platinum versus atezolizumab plus EP in extensive-stage small cell lung cancer. Journal Of Clinical Oncology 2022, 40: tps8606-tps8606. DOI: 10.1200/jco.2022.40.16_suppl.tps8606.Peer-Reviewed Original ResearchExtensive-stage small-cell lung cancerEtoposide/platinumPatient-reported outcomesSmall cell lung cancerPhase 3 studyLung cancerRECIST v1.1ECOG PSDisease progressionBlinded independent central reviewNeurologic paraneoplastic syndromesUntreated ES-SCLCFirst-line pembrolizumabFirst-line treatmentInterstitial lung diseaseCell lung cancerDuration of responseT cell immunoreceptorIndependent central reviewWithdrawal of consentPretreatment tumor samplesNew anticancer treatmentsCare immunotherapyCTCAE v5.0Measurable disease
2021
Therapeutic Advances in Small Cell Lung Cancer Management
Newton B, Chiang A. Therapeutic Advances in Small Cell Lung Cancer Management. Current Cancer Research 2021, 175-195. DOI: 10.1007/978-3-030-74028-3_8.Peer-Reviewed Original ResearchSmall cell lung cancer managementSmall cell lung cancer treatmentSmall cell lung cancerCell lung cancer managementCell lung cancer treatmentLung cancer managementCell lung cancerLung cancer treatmentRecalcitrant malignancySignificant management challengesLung cancerTherapeutic advancesCancer managementTherapeutic interventionsCancer treatmentNew targetsCell cycle regulationCycle regulationImmunotherapyMalignancyCancerDiseasePhysicians
2020
359 AMG 757, a half-life extended bispecific T-cell engager (BiTE®) immune therapy against DLL3 in SCLC: phase 1 interim results
Borghaei H, Boyer M, Johnson M, Govindan R, Rodrigues L, Blackhall F, Boosman R, Champiat S, Hummel H, Lai W, Udagawa H, Chiang A, Dowlati A, Hann C, Salgia R, Vokes E, Minocha M, Hashemi-Sadraei N, Shetty A, Smit M, Yang H, Owonikoko T. 359 AMG 757, a half-life extended bispecific T-cell engager (BiTE®) immune therapy against DLL3 in SCLC: phase 1 interim results. Journal For ImmunoTherapy Of Cancer 2020, 8: a384-a384. DOI: 10.1136/jitc-2020-sitc2020.0359.Peer-Reviewed Original ResearchDelta-like ligand 3Small cell lung cancerCytokine release syndromeAdverse eventsImmune therapyPD-1/PD-L1 treatmentDose levelsRefractory small cell lung cancerOngoing phase 1 studiesTreatment-emergent adverse eventsTumor cellsCommon adverse eventsMedian prior linesMedian treatment durationPD-L1 treatmentPlatinum-based regimenAcceptable safety profileDose-proportional increaseFurther dose escalationPhase 1 studyCell lung cancerDuration of responseEthics BoardAnti-tumor activityECOG PSAssociation Between Prophylactic Cranial Irradiation and Improved Overall Survival in Small Cell Lung Cancer
Yang D, Park H, Jairam V, Decker R, Chiang A, Gross C, Yu J. Association Between Prophylactic Cranial Irradiation and Improved Overall Survival in Small Cell Lung Cancer. International Journal Of Radiation Oncology • Biology • Physics 2020, 108: e106. DOI: 10.1016/j.ijrobp.2020.07.1223.Peer-Reviewed Original ResearchUse of prophylactic cranial irradiation in patients with extensive-stage small cell lung cancer receiving immunotherapy.
Yang D, Jairam V, Park H, Decker R, Chiang A, Gross C, Yu J. Use of prophylactic cranial irradiation in patients with extensive-stage small cell lung cancer receiving immunotherapy. Journal Of Clinical Oncology 2020, 38: e19309-e19309. DOI: 10.1200/jco.2020.38.15_suppl.e19309.Peer-Reviewed Original ResearchExtensive-stage small-cell lung cancerFirst-line chemoSmall cell lung cancerES-SCLC patientsCell lung cancerSurvival benefitIO patientsLung cancerStudy periodFirst-line atezolizumabInitial systemic therapyProphylactic cranial irradiationFirst-line chemotherapyRetrospective cohort analysisContemporary practice patternsDe-identified databaseUse of PCIEffectiveness of PCICHEMO patientsCranial irradiationIO therapyPCI useSystemic therapyMRI surveillancePractice patternsA multi-stakeholder platform to prospectively link longitudinal real-world clinico-genomic, imaging, and outcomes data for patients with metastatic lung cancer.
Lu M, Walia G, Schulze K, Doral M, Maund S, Gaffey S, Cabili M, Bourla A, Green R, Santos E, Herbst R, Chiang A, Schwartzberg L. A multi-stakeholder platform to prospectively link longitudinal real-world clinico-genomic, imaging, and outcomes data for patients with metastatic lung cancer. Journal Of Clinical Oncology 2020, 38: tps2087-tps2087. DOI: 10.1200/jco.2020.38.15_suppl.tps2087.Peer-Reviewed Original ResearchCell lung cancerLung cancerOverall survivalOutcome dataExtensive-stage small-cell lung cancerMetastatic non-small cell lung cancerNon-small cell lung cancerSmall cell lung cancerReal-world clinical outcomesGenomic profilingFirst tumor assessmentFlatiron Health networkTechnology-enabled abstractionLines of therapyMetastatic lung cancerEnd of treatmentWithdrawal of consentClinical data pointsEnd of studyTumor DNA ProfilingAnti-neoplastic treatmentCase report formsTumor tissue samplesBlood genomic profilingElectronic health recordsPhase I study of AMG 757, a half-life extended bispecific T-cell engager (HLE BiTE immune therapy) targeting DLL3, in patients with small cell lung cancer (SCLC).
Owonikoko T, Borghaei H, Champiat S, Paz-Ares L, Govindan R, Boyer M, Johnson M, Udagawa H, Hummel H, Salgia R, Blackhall F, Boosman R, Lai W, Dowlati A, Vokes E, Hann C, Chiang A, Endraca M, Soman N, Smit M. Phase I study of AMG 757, a half-life extended bispecific T-cell engager (HLE BiTE immune therapy) targeting DLL3, in patients with small cell lung cancer (SCLC). Journal Of Clinical Oncology 2020, 38: tps9080-tps9080. DOI: 10.1200/jco.2020.38.15_suppl.tps9080.Peer-Reviewed Original ResearchDelta-like ligand 3Small cell lung cancerImmune therapyT cellsRefractory small cell lung cancerECOG performance status 0PD-1 pathway inhibitorsPlatinum-based chemotherapy regimenBispecific T-cell engagersTumor cellsAdequate organ functionMost SCLC tumorsPerformance status 0Phase 2 doseSafety/tolerabilitySymptomatic brain metastasesAntitumor activityAggressive neuroendocrine tumorPhase 1 studyCancer cellsCell lung cancerPreliminary antitumor activityT-cell engagersDirect antitumor effectsPromising therapeutic target
2019
Benefit of combining local treatment and systemic therapy for stage IV NSCLC: Results from the National Cancer Database.
Dendy Case M, Uhlig J, Blasberg J, Boffa D, Chiang A, Gettinger S, Kim H. Benefit of combining local treatment and systemic therapy for stage IV NSCLC: Results from the National Cancer Database. Journal Of Clinical Oncology 2019, 37: 8545-8545. DOI: 10.1200/jco.2019.37.15_suppl.8545.Peer-Reviewed Original ResearchNon-small cell lung cancerNational Cancer DatabaseStage IV non-small cell lung cancerStage IV NSCLC patientsSystemic therapyOverall survivalSurgical resectionPatient demographicsNSCLC patientsCancer DatabaseMultivariable Cox proportional hazards modelsSquamous cell carcinoma patientsPropensity scoreMultivariable logistic regression modelCox proportional hazards modelSuperior overall survivalCell carcinoma patientsCell lung cancerLung cancer treatmentProportional hazards modelLogistic regression modelsLimited nodalTA patientsMetastatic diseaseMultivariable adjustment
2018
Final Results of a Phase I Prospective Trial Evaluating the Combination of Stereotactic Body Radiation Therapy (SBRT) with Concurrent Pembrolizumab in Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC) or Melanoma
Campbell A, Herbst R, Gettinger S, Goldberg S, Kluger H, Chiang A, Lilenbaum R, Schalper K, Sowell R, Kaech S, Decker R. Final Results of a Phase I Prospective Trial Evaluating the Combination of Stereotactic Body Radiation Therapy (SBRT) with Concurrent Pembrolizumab in Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC) or Melanoma. International Journal Of Radiation Oncology • Biology • Physics 2018, 102: s18-s19. DOI: 10.1016/j.ijrobp.2018.06.134.Peer-Reviewed Original ResearchDurability of brain metastasis response and overall survival in patients with non-small cell lung cancer (NSCLC) treated with pembrolizumab.
Goldberg S, Gettinger S, Mahajan A, Herbst R, Chiang A, Lilenbaum R, Jilaveanu L, Rowen E, Gerrish H, Komlo A, Wei W, Chiang V, Kluger H. Durability of brain metastasis response and overall survival in patients with non-small cell lung cancer (NSCLC) treated with pembrolizumab. Journal Of Clinical Oncology 2018, 36: 2009-2009. DOI: 10.1200/jco.2018.36.15_suppl.2009.Peer-Reviewed Original ResearchFinal results of a phase I prospective trial evaluating the combination of stereotactic body radiotherapy (SBRT) with concurrent pembrolizumab in patients with metastatic non-small cell lung cancer (NSCLC) or melanoma.
Campbell A, Herbst R, Gettinger S, Goldberg S, Kluger H, Chiang A, Lilenbaum R, Schalper K, Sowell R, Kaech S, Decker R. Final results of a phase I prospective trial evaluating the combination of stereotactic body radiotherapy (SBRT) with concurrent pembrolizumab in patients with metastatic non-small cell lung cancer (NSCLC) or melanoma. Journal Of Clinical Oncology 2018, 36: 9099-9099. DOI: 10.1200/jco.2018.36.15_suppl.9099.Peer-Reviewed Original ResearchChapter 7 A Practical Approach to Management of Small Cell Lung Cancer
Talsania A, Chiang A. Chapter 7 A Practical Approach to Management of Small Cell Lung Cancer. 2018, 117-129. DOI: 10.1016/b978-0-323-48565-4.00007-2.Peer-Reviewed Original ResearchSmall cell lung cancerCell lung cancerLung cancerLimited stage small cell lung cancerStage small cell lung cancerSecond-line treatment optionAddition of immunotherapyTime of presentationNCCN guidelinesExtensive diseaseImmunotherapy agentsFrontline treatmentCombination therapyTreatment optionsAggressive formSCLC biologyRB1 lossCancerTherapeutic developmentDiseaseWidespread diseasePossible targetsFunction mutationsContributing factorMolecular determinants
2017
Racial disparities in the use of programmed death-1 checkpoint inhibitors.
O'Connor J, Seidl-Rathkopf K, Torres A, You P, Nussbaum N, Fessele K, Darius K, Adelson K, Yin E, Presley C, Chiang A, Ross J, Abernethy A, Gross C. Racial disparities in the use of programmed death-1 checkpoint inhibitors. Journal Of Clinical Oncology 2017, 35: 3068-3068. DOI: 10.1200/jco.2017.35.15_suppl.3068.Peer-Reviewed Original ResearchDeath-1 checkpoint inhibitorsElectronic health record databaseLines of therapySystemic therapyCheckpoint inhibitorsCancer clinicRacial disparitiesAdvanced non-small cell lung cancerNon-small cell lung cancerMetastatic renal cell carcinomaAnti-PD1 treatmentCell lung cancerRenal cell carcinomaHealth record databaseSignificant racial disparitiesNew cancer drugsSquamous histologyStudy drugReal-world practiceAdvanced melanomaTherapy linesWhite patientsMale sexCell carcinomaLung cancerDisparities in next generation sequencing in a population-based community cohort of patients with advanced non-small cell lung cancer.
Presley C, Soulos P, Chiang A, Longtine J, Adelson K, Herbst R, Nussbaum N, Sorg R, Abernethy A, Agarwala V, Gross C. Disparities in next generation sequencing in a population-based community cohort of patients with advanced non-small cell lung cancer. Journal Of Clinical Oncology 2017, 35: 6563-6563. DOI: 10.1200/jco.2017.35.15_suppl.6563.Peer-Reviewed Original ResearchNon-small cell lung cancerAdvanced non-small cell lung cancerCell lung cancerNGS testingLung cancerBiomarker testingOncology practiceNext-generation sequencingNon-squamous non-small cell lung cancerPopulation-based community cohortReal-world clinical practiceMulti-gene panel testingInsurance-related disparitiesAdvanced lung cancerFirst-line treatmentHistory of smokingRetrospective observational studyElectronic health record dataWorld clinical practiceClustering of patientsHealth record dataYounger patientsMedian agePatient characteristicsWhite patients